🚀 VC round data is live in beta, check it out!
AbbVie Valuation Multiples
Discover revenue and EBITDA valuation multiples for AbbVie and similar public comparables like Procter & Gamble, Roche, AstraZeneca, Merck and more.
AbbVie Overview
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Founded
2012
HQ
Employees
57.0K
Website
Financials (LTM)
EV
$434B
AbbVie Financials
AbbVie reported last 12-month revenue of $63B and EBITDA of $27B.
In the same LTM period, AbbVie generated $53B in gross profit, $27B in EBITDA, and $20B in net income.
Revenue (LTM)
AbbVie P&L
In the most recent fiscal year, AbbVie reported revenue of $61B and EBITDA of $24B.
AbbVie expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $63B | XXX | $61B | XXX | XXX | XXX |
| Gross Profit | $53B | XXX | $43B | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $27B | XXX | $24B | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | 42% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $20B | XXX | $18B | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 29% | XXX | XXX | XXX |
| Net Debt | — | — | $62B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AbbVie Stock Performance
AbbVie has current market cap of $372B, and enterprise value of $434B.
Market Cap Evolution
AbbVie's stock price is $210.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $434B | $372B | 1.8% | XXX | XXX | XXX | $10.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbbVie Valuation Multiples
AbbVie trades at 6.9x EV/Revenue multiple, and 16.4x EV/EBITDA.
EV / Revenue (LTM)
AbbVie Financial Valuation Multiples
As of April 15, 2026, AbbVie has market cap of $372B and EV of $434B.
Equity research analysts estimate AbbVie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AbbVie has a P/E ratio of 18.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $372B | XXX | $372B | XXX | XXX | XXX |
| EV (current) | $434B | XXX | $434B | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 16.4x | XXX | 17.9x | XXX | XXX | XXX |
| EV/EBIT | 16.6x | XXX | 18.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.2x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | 18.7x | XXX | 20.9x | XXX | XXX | XXX |
| EV/FCF | 21.2x | XXX | 23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AbbVie Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AbbVie Margins & Growth Rates
AbbVie's revenue in the last 12 month grew by 9%.
AbbVie's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.4M for the same period.
AbbVie's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AbbVie's rule of X is 72% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
AbbVie Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AbbVie Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca | XXX | XXX | XXX | XXX | XXX | XXX |
| Merck | XXX | XXX | XXX | XXX | XXX | XXX |
| Novartis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AbbVie M&A Activity
AbbVie acquired XXX companies to date.
Last acquisition by AbbVie was on XXXXXXXX, XXXXX. AbbVie acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AbbVie
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAbbVie Investment Activity
AbbVie invested in XXX companies to date.
AbbVie made its latest investment on XXXXXXXX, XXXXX. AbbVie invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AbbVie
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AbbVie
| When was AbbVie founded? | AbbVie was founded in 2012. |
| Where is AbbVie headquartered? | AbbVie is headquartered in United States. |
| How many employees does AbbVie have? | As of today, AbbVie has over 57K employees. |
| Who is the CEO of AbbVie? | AbbVie's CEO is Robert A. Michael. |
| Is AbbVie publicly listed? | Yes, AbbVie is a public company listed on NYSE. |
| What is the stock symbol of AbbVie? | AbbVie trades under ABBV ticker. |
| When did AbbVie go public? | AbbVie went public in 2012. |
| Who are competitors of AbbVie? | AbbVie main competitors are Procter & Gamble, Roche, AstraZeneca, Merck. |
| What is the current market cap of AbbVie? | AbbVie's current market cap is $372B. |
| What is the current revenue of AbbVie? | AbbVie's last 12 months revenue is $63B. |
| What is the current revenue growth of AbbVie? | AbbVie revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of AbbVie? | Current revenue multiple of AbbVie is 6.9x. |
| Is AbbVie profitable? | Yes, AbbVie is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AbbVie? | AbbVie's last 12 months EBITDA is $27B. |
| What is AbbVie's EBITDA margin? | AbbVie's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of AbbVie? | Current EBITDA multiple of AbbVie is 16.4x. |
| What is the current FCF of AbbVie? | AbbVie's last 12 months FCF is $20B. |
| What is AbbVie's FCF margin? | AbbVie's last 12 months FCF margin is 33%. |
| What is the current EV/FCF multiple of AbbVie? | Current FCF multiple of AbbVie is 21.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.